OM
CNCE

Opaleye Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Opaleye Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-254,000
Closed -$3.21M – 68
2020
Q4 		$3.21M Buy
254,000
+154,000
+154% +$1.76M 0.42% 48
2020
Q3 		$982K Buy
+100,000
New +$985K 0.19% 48

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Opaleye Management's CNCE Position: Q1 2021 in Review

Opaleye Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2021, closing a stake of 254,000 shares — an estimated $3.21M sold.

Opaleye Management first reported a position in CNCE in Q3 2020 and held it in 2 quarters. The position peaked at $3.21M in Q4 2020. 91 funds tracked by Wall St. Rank hold CNCE as of Q1 2021.

  • Opaleye Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Opaleye Management sold 254,000 Concert Pharmaceuticals, Inc. shares in Q1 2021, an estimated $3.21M.
  • Opaleye Management first reported a position in Concert Pharmaceuticals, Inc. in Q3 2020 and held it in 2 quarters.
  • Opaleye Management's Concert Pharmaceuticals, Inc. position peaked at $3.21M in Q4 2020.
  • 91 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2021.

Based on Opaleye Management's 13F filing for Q1 2021, filed 18 May 2021.